Deerfield Management Company, L.P. (Series C) Amicus Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 21,723 shares of FOLD stock, worth $210,278. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,723
Previous 29,752
26.99%
Holding current value
$210,278
Previous $295,000
21.36%
% of portfolio
0.0%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding FOLD
# of Institutions
312Shares Held
314MCall Options Held
516KPut Options Held
833K-
Vanguard Group Inc Valley Forge, PA28.8MShares$279 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY28.1MShares$272 Million7.83% of portfolio
-
Black Rock Inc. New York, NY24.4MShares$236 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA24MShares$232 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY23.2MShares$224 Million3.72% of portfolio
About AMICUS THERAPEUTICS, INC.
- Ticker FOLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 280,497,984
- Market Cap $2.72B
- Description
- Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...